Abstract
Huron Consulting is scheduled to report its quarterly results on May 05, 2026 Post Market, with market expectations pointing to year-over-year growth in revenue and adjusted earnings as investors focus on segment momentum, margin resilience, and delivery capacity.Market Forecast
Consensus for the current quarter anticipates revenue of 437.07 million US dollars, up 12.28% year over year, adjusted EPS of 1.60, up 38.67% year over year, and EBIT of 38.85 million US dollars, up 9.42% year over year. Forecast margin details were not explicitly indicated, though the comparison base includes a last-quarter gross margin of 33.71% and a net profit margin of 7.09%.The main business outlook points to continued strength in core client demand and digitally enabled engagements, with the demand backdrop in healthcare and commercial supported by ongoing interest in efficiency, automation, and analytics solutions. The most promising segment is healthcare, which contributed approximately 213.08 million US dollars in the prior quarter (about 49.29% of revenue) and, according to recent commentary, delivered double-digit year-over-year growth that is expected to continue driving expansion.
Last Quarter Review
Huron Consulting delivered revenue of 432.28 million US dollars, a gross profit margin of 33.71%, GAAP net profit attributable to shareholders of 30.65 million US dollars for a 7.09% net profit margin, and adjusted EPS of 2.17; revenue grew 11.29% year over year and adjusted EPS rose 14.21% year over year. Net profit increased 77% sequentially and adjusted EPS beat consensus by 0.22 (an 11.28% upside), while EBIT climbed 26.39% year over year to 61.06 million US dollars. Segment performance was led by healthcare at approximately 213.08 million US dollars (49.29% of the quarter), followed by education at 127.23 million US dollars and commercial at 82.71 million US dollars, with reimbursable expenses of 9.24 million US dollars; recent commentary highlighted double-digit year-over-year growth in healthcare and commercial supported by new AI and automation offerings.Current Quarter Outlook
Main business: Healthcare consulting execution and mix
Healthcare remains the company’s largest revenue contributor, representing roughly half of quarterly revenue on the latest mix, and it is expected to anchor growth again in the current period. The segment has benefited from sustained demand for operational improvement, revenue cycle optimization, workforce productivity, and technology-enabled transformation, including AI- and automation-led initiatives noted after the recent print. This mix supports revenue stability while giving management levers to protect utilization and pricing. With hospital and health system clients prioritizing throughput, coding accuracy, and cost alignment, the project pipeline supports both time-and-materials and fixed-fee work that can balance near-term margins. The most immediate swing variables in this segment are consultant utilization levels and the proportion of higher-value digital and analytics project work, both of which can support gross margin near or above last quarter’s baseline if maintained. In the quarter now under view, incremental contributions from recent acquisitions and cross-sell into larger health-system accounts should bolster backlog conversion and underpin the revenue estimate of 437.07 million US dollars across the enterprise.Most promising business: Commercial digital and analytics momentum
The commercial segment has emerged as an important growth lever, aided by increasing demand for analytics, cloud transformation, and operating model redesign. Analyst commentary tied recent outperformance to digitally enabled work, including AI and automation launches that raised the win rate in complex, multi-solution deals; this backdrop points to healthy deal flow and positive project starts through the quarter. The segment’s scale in the last reported period—approximately 82.71 million US dollars—combined with double-digit year-over-year growth indications suggests that it can outpace the broader company growth rate if execution on new logos and cross-sell into existing clients continues. Gross margin sensitivity here comes from delivery mix: higher software-enabled and data projects tend to carry better economics than traditional advisory, and a higher mix of these projects could offset wage inflation or ramp costs from hiring. From a revenue recognition standpoint, fixed-fee digital projects can introduce timing variability; however, the breadth of the pipeline helps smooth quarter-to-quarter fluctuations. If the commercial practice sustains its recent cadence, it should contribute an outsized share of incremental EBIT versus its revenue share, supporting the forecast of 38.85 million US dollars in EBIT for the quarter.Key stock-price drivers this quarter
The first driver is project mix and utilization, which together influence gross profit and operating leverage. Utilization near the upper end of historical ranges, combined with steady bill rates, would help keep gross margin close to or above the recent 33.71% level, while any shift toward lower-utilization weeks or higher ramp-related training time could exert modest pressure. Mix also matters: time-and-materials work provides flexibility but can be less accretive than complex fixed-fee, digitally intensive engagements; the latter, if executed cleanly, can expand margins even at similar revenue levels.The second driver is backlog conversion and new bookings in healthcare and commercial. Evidence of durable demand—such as multi-quarter program awards, broader scope expansions, or accelerated starts—would reinforce confidence in the 12.28% year-over-year revenue growth forecast. Conversely, elongated client approval cycles or pushouts of transformation initiatives could impact in-quarter revenue realization more than demand indicators suggest, making commentary on start dates and pipeline composition pivotal for interpreting the run-rate into the next quarter. Management’s recent emphasis on AI and automation wins, alongside cross-sell synergies from acquisitions, indicates a constructive setup for backlog conversion if delivery capacity remains aligned.
The third driver is operating expense discipline and the path of adjusted EPS. The company posted 2.17 in adjusted EPS last quarter and is guided to 1.60 in the current quarter on a year-over-year increase of 38.67%, implying seasonal or mix-related normalization and a lower operating leverage profile than the seasonally strong prior quarter. Achieving the EPS estimate will depend on balancing delivery costs, maintaining consultant utilization, and containing overhead absorption as the company continues to invest in digital capabilities. Favorable revenue mix and high-quality execution on fixed-fee projects could more than offset wage inflation or higher subcontracting costs, keeping margins healthy despite a potentially different seasonal pattern.
A supplementary consideration is reimbursable expenses and working capital dynamics. While reimbursable expenses (approximately 9.24 million US dollars last quarter) are typically lower-margin pass-throughs, they can influence revenue optics without materially affecting profit. Cash conversion and receivables trends are worth monitoring in a growth quarter, particularly if larger transformation programs ramp concurrently. Given the Post Market release time on May 05, 2026, management’s qualitative guidance on pipeline, pricing, and utilization will likely guide next-day trading as investors recalibrate expectations for the second quarter.
Analyst Opinions
Bullish opinions dominate recent commentary, with a ratio of 3 bullish to 0 bearish. Wedbush reaffirmed an Outperform view with a 200 US dollars price target, emphasizing that Huron Consulting is positioned to capitalize on double-digit growth across core verticals and highlighting strong healthcare and commercial momentum alongside a growing suite of AI and automation services. In a separate note, Wedbush indicated that management views the company as relatively insulated from geopolitical risks given that approximately four-fifths of revenue is tied to US healthcare and education end markets, reinforcing the demand stability underlying the current quarter’s forecasts. Barrington maintained a Buy rating with a 207 US dollars target, citing consistent execution and a constructive pipeline that supports above-market growth and continued margin progress as digital engagements scale. Truist also reiterated a Buy stance, pointing to sustained client demand and an expanding opportunity set in technology-enabled transformation projects.These bullish stances cohere with the quarter’s quantitative markers: a 12.28% year-over-year revenue growth estimate to 437.07 million US dollars and a 38.67% rise in adjusted EPS to 1.60 indicate healthy operating momentum, while EBIT forecast growth of 9.42% to 38.85 million US dollars suggests manageable incrementals despite investments in capabilities and delivery capacity. The analyst focus on healthcare and commercial aligns with the prior quarter’s revenue mix, where healthcare contributed about 213.08 million US dollars and commercial about 82.71 million US dollars, confirming the areas most likely to carry near-term upside. Commentary on AI and automation resonates with client trends, where analytics-rich and automation-heavy initiatives can expand project scope, raise win rates, and deliver better unit economics than traditional advisory work.
From an expectations perspective, the bullish consensus essentially frames three validation points for the print. First, revenue realization should affirm demand durability through sequential seasonality, with healthcare anchoring growth and commercial accelerating on digital programs. Second, margin commentary should indicate that utilization and pricing are holding near recent levels, or that mix shifts toward higher-value digital work are offsetting any seasonal troughs in utilization, maintaining the company’s ability to deliver mid-30s gross margin. Third, bookings and pipeline disclosures should reinforce the trajectory into the next quarter, with multi-quarter awards or expansions serving as proof points for sustained double-digit growth potential. If the company demonstrates progress across these vectors, the analyst majority expects positive estimate revisions or at least higher confidence in the current-year framework.
The preponderance of Buy ratings also reflects an assessment that recent acquisitions and the broadened service portfolio are enhancing cross-sell, improving competitive win rates, and supporting larger programmatic engagements. This structural setup tends to improve visibility as engagements transition from discrete advisory tasks to multi-phase transformations, which often carry stronger margin characteristics. Analysts highlight that management’s focus on operational delivery and capacity balancing—keeping headcount and subcontracting aligned with demand—should help preserve margin even as the mix evolves. On balance, the prevailing view anticipates that the company’s healthcare-led foundation, commercial digital momentum, and disciplined cost management can collectively support the quarter’s revenue and earnings forecasts while laying groundwork for continued growth in subsequent quarters.